N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Phase 1 N=32 PF-04634817 Renal Impairment Study
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
N/A N=206 HIV and Kidney Function Study
HIV Infections · AIDS
Primary: Performance of Glomerular Filtration Rate (GFR) Estimating Equations — 10.9; 5.4; 4.3; 6.4 mL/min per 1.73 m^2
Phase 1 N=24 A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Impaired Renal Function
Primary: Pharmacokinetic Parameters- Plasma AUC0-24 — 16877.94; 32787.41; 64895.29; 15506.68 ng*h/mL
Phase 1 N=16 Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
Phase 1 N=20 A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
Renal Insufficiency · Healthy
Primary: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) — 3.97; 7.88…
Phase 1 N=29 A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Pneumonia
Primary: Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose — 17700; 22070; 28940; 10340 nanogram per milliliter (ng/mL)
N/A N=120 Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation
Kidney Diseases · Kidney Failure, Chronic · Kidney Failure
Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l
N/A N=1,237 Renal Safety of Bowel Preparation With Polyethylene Glycol
Acute Kidney Injury
Primary: Number of Participants With Acute Renal Injury Which Included Acute Renal Dysfunction and Acute Kidney Injury — 32 participants
N/A N=10 Measurement of Kidney Blood Flow and Oxygen Levels by MRI
Chronic Kidney Disease
Primary: Measurement of Renal Blood Flow of the Kidney by the PAH Method — 190 ml/min
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 1 N=27 Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Phase 1 N=31 Mild, Moderate and Severe Renal Impairment Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Phase 2 N=33 CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Cardiorenal Syndrome (CRS)
Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26
Phase 2 N=22 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04
Phase 1 N=30 Renal Impairment Study of PF-06700841
Healthy Volunteer · Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants…
N/A N=128 An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
Kidney Transplantation
Primary: Creatinine Clearance at 1 Month After Transplantation — 65.82 mL/min
Phase 1 N=24 Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
Renal Impairment
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 268; 370; 396; 615 nanogram*hour/milliliter (ng*hr/mL)
Phase 2 N=32 Exercise Intolerance in Renal Failure
Kidney Failure, Chronic
Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute
Phase 1 N=23 A Renal Impairment Study for PF-04965842
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1174; 1626; 1164 nanogram per milliliter (ng/mL)
Phase 3 N=78 REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
Liver Transplantation
Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013
Phase 2 N=80 The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.
Cardiorenal Syndrome
Primary: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values — 8; 5 Participants
Phase 1 N=32 Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Hepatitis C
Primary: AUC0-∞ — 76500; 86900; 136000; 129000 ng*h/mL
Phase 1 N=36 Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
Hepatitis C
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Daclatasvir — 11215.264; 21261.199; 24789.951; 21946.450…
Phase 1 N=16 Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
Renal Impairment
Primary: Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757 — 3.81; 4.94; 533; 759 ng/mL
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 1 N=29 Lorlatinib Renal Impairment Study
Renal Impairment
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib — 8329; 8683; 9890; 11760 ng*hr/mL
Phase 4 N=511 A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
Kidney Diseases · Coronary Artery Disease
Primary: Number of Subject With Serious Treatment Emergent Adverse Events (TEAE) — 0; 0 Subjects